Market News

As Achillion Pharmaceuticals (ACHN) Share Value Were Volatile, Dafna Capital Management Has Upped Its Stake by $1.81 Million; Altavista Wealth Management Trimmed Its Target (TGT) Stake by $514,112

Nathan Fischel increased its stake in Achillion Pharmaceuticals (ACHN) by 169.52% based on its latest 2017Q3 regulatory filing with the SEC. Dafna Capital Management Llc bought 451,772 shares as the company’s stock 0.00% . The hedge fund run by Nathan Fischel held 718,272 shares of the health care company at the end of 2017Q3, valued at $3.23 million, up from 266,500 at the end of the previous reported quarter. Dafna Capital Management Llc who had been investing in Achillion Pharmaceuticals for a number of months, seems to be bullish on the $413.57M market cap company. The stock increased 0.67% or $0.02 during the last trading session, reaching $3. About 761,932 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 47.61% since February 14, 2017 and is downtrending. It has underperformed by 64.31% the S&P500.

Altavista Wealth Management Inc decreased its stake in Target Corporation (TGT) by 31.69% based on its latest 2017Q3 regulatory filing with the SEC. Altavista Wealth Management Inc sold 8,864 shares as the company’s stock declined 14.90% while stock markets rallied. The institutional investor held 19,106 shares of the department and specialty retail stores company at the end of 2017Q3, valued at $1.13M, down from 27,970 at the end of the previous reported quarter. Altavista Wealth Management Inc who had been investing in Target Corporation for a number of months, seems to be less bullish one the $41.24 billion market cap company. The stock increased 2.68% or $1.98 during the last trading session, reaching $75.86. About 4.47 million shares traded. Target Corporation (NYSE:TGT) has declined 16.51% since February 14, 2017 and is downtrending. It has underperformed by 33.21% the S&P500.

Analysts await Target Corporation (NYSE:TGT) to report earnings on February, 27. They expect $1.19 earnings per share, down 17.93% or $0.26 from last year’s $1.45 per share. TGT’s profit will be $646.84 million for 15.94 P/E if the $1.19 EPS becomes a reality. After $0.91 actual earnings per share reported by Target Corporation for the previous quarter, Wall Street now forecasts 30.77% EPS growth.

Among 28 analysts covering Target Corporation (NYSE:TGT), 8 have Buy rating, 3 Sell and 17 Hold. Therefore 29% are positive. Target Corporation had 82 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was upgraded by Vetr to “Buy” on Tuesday, August 25. The company was maintained on Monday, September 18 by Stifel Nicolaus. Bernstein maintained the shares of TGT in report on Thursday, December 14 with “Buy” rating. Citigroup maintained Target Corporation (NYSE:TGT) on Thursday, May 19 with “Buy” rating. The firm has “Hold” rating by Stifel Nicolaus given on Wednesday, October 18. The rating was upgraded by M Partners to “Buy” on Thursday, August 17. The rating was maintained by Citigroup on Thursday, August 18 with “Buy”. The rating was downgraded by Wolfe Research on Friday, April 29 to “Peer Perform”. The stock of Target Corporation (NYSE:TGT) has “Neutral” rating given on Thursday, November 19 by UBS. The company was maintained on Thursday, February 4 by Piper Jaffray.

Investors sentiment decreased to 0.96 in 2017 Q3. Its down 0.37, from 1.33 in 2017Q2. It is negative, as 16 investors sold ACHN shares while 37 reduced holdings. 17 funds opened positions while 34 raised stakes. 105.14 million shares or 4.06% more from 101.03 million shares in 2017Q2 were reported. Zurcher Kantonalbank (Zurich Cantonalbank) invested 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Nj State Employees Deferred Compensation Plan invested in 30,000 shares. Meeder Asset Mngmt Inc reported 934 shares stake. Dekabank Deutsche Girozentrale stated it has 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Millennium Mgmt Ltd Llc holds 0% or 406,200 shares in its portfolio. Legal And General Grp Public holds 0% or 46,345 shares. State Board Of Administration Of Florida Retirement Sys accumulated 75,246 shares. Moreover, State Bank Of Montreal Can has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 4,118 shares. Armistice Capital Ltd stated it has 1.02 million shares. Vanguard, a Pennsylvania-based fund reported 9.42M shares. Moreover, Price T Rowe Associate Md has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 25,228 shares. Geode Capital Mngmt Ltd accumulated 1.04 million shares. Shell Asset owns 90,395 shares or 0.02% of their US portfolio. Raymond James has invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). California Employees Retirement Sys owns 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 163,700 shares.

Among 11 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. Achillion Pharma had 26 analyst reports since August 13, 2015 according to SRatingsIntel. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Sell” rating by Chardan Capital Markets on Thursday, July 14. Robert W. Baird maintained the stock with “Hold” rating in Monday, October 23 report. The rating was initiated by FBR Capital on Wednesday, February 7 with “Hold”. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Market Outperform” rating by JMP Securities on Thursday, July 7. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has “Outperform” rating given on Thursday, September 15 by FBR Capital. As per Monday, September 11, the company rating was maintained by Robert W. Baird. Robert W. Baird downgraded Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) on Thursday, August 10 to “Neutral” rating. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Outperform” rating by Robert W. Baird on Friday, February 26. Chardan Capital Markets maintained the shares of ACHN in report on Friday, September 23 with “Sell” rating. The firm has “Buy” rating by Leerink Swann given on Monday, December 11.

Leave a Reply

Your email address will not be published. Required fields are marked *